Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 27;10(9):165.
doi: 10.3390/life10090165.

Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?

Affiliations
Review

Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?

Filiberto Fausto Mottola et al. Life (Basel). .

Abstract

As of January 2020, a new pandemic has spread from Wuhan and caused thousands of deaths worldwide. Several studies have observed a relationship between coronavirus disease (COVID-19) infection and the cardiovascular system with the appearance of myocardial damage, myocarditis, pericarditis, heart failure and various arrhythmic manifestations, as well as an increase in thromboembolic risk. Cardiovascular manifestations have been highlighted especially in older and more fragile patients and in those with multiple cardiovascular risk factors such as cancer, diabetes, obesity and hypertension. In this review, we will examine the cardiac involvement associated with SARS-CoV-2 infection, focusing on the pathophysiological mechanism underlying manifestations and their clinical implication, taking into account the main scientific papers published to date.

Keywords: SARS-CoV-2 infection; cardiovascular system; heart failure; myocardial injury.

PubMed Disclaimer

Conflict of interest statement

The manuscript has been read and approved by all authors and has not been submitted for publication to other journals. We also declare that we have no conflict of interest in connection with this paper.

Figures

Figure 1
Figure 1
SARS-CoV-2 and cardiovascular involvement.
Figure 2
Figure 2
SARS-CoV-2 and management. Heart Failure (HF).
Figure 3
Figure 3
SARS-CoV-2 and ACS management. Type 2 myocardial infarction (type II IM); non-ST segment elevation myocardial infarction (NSTEMI); unstable angina (UA); ST elevation myocardial infarction (STEMI); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); personal protective equipment (PPE).
Figure 4
Figure 4
Arrhythmic risk management.

Similar articles

Cited by

References

    1. Epidemiology Working Group for NCIP Epidemic Response The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin. J. Epidemiol. 2020;41:145–151. - PubMed
    1. National Health Commission of the People’s Republic of China Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition) [(accessed on 25 July 2020)];2020 Available online: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html.
    1. Macera M., De Angelis G., Sagnelli C., Coppola N. Vanvitelli COVID-19 group Clinical Presentation of COVID-19: Case Series and Review of the Literature. Int. J. Environ. Res. Public Health. 2020;17:5062. doi: 10.3390/ijerph17145062. - DOI - PMC - PubMed
    1. Sagnelli C., Gentile V., Tirri R., Macera M., Cappabianca S., Ciccia F., Coppola N. Vanvitelli COVID-19 group Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient. J. Infect. 2020 doi: 10.1016/j.jinf.2020.05.043. - DOI - PMC - PubMed
    1. Liu P.P., Blet A., Smyth D., Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142:68–78. doi: 10.1161/CIRCULATIONAHA.120.047549. - DOI - PubMed